Essential Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Essential Partners’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.62K	Sell	1,551 -1,258	-45%	-$6.76K	﹤0.01%	1324
2026 Q2	$17.2K	Sell	2,809 -433	-13%	-$2.83K	0.01%	968
2026 Q1	$22.4K	Buy	3,242 +454	+16%	+$3.5K	0.01%	883
2025 Q4	$24.6K	Sell	2,788 -1,024	-27%	-$5.64K	0.01%	831
2025 Q3	$19K	Buy	3,812 +3,345	+716%	+$15.5K	0.01%	909
2025 Q2	$2.2K	Buy	+467	New	+$2.04K	﹤0.01%	1286

Other funds holding VNDA

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

CFS

CGC Financial Services Lake Oswego, Oregon $451M AUM 11.72% 1-Year Est. Return

Essential Partners's VNDA Position: Q3 2026 in Review

Essential Partners reduced its Vanda Pharmaceuticals (VNDA) stake by 45% in Q3 2026, selling an estimated $6.76K and leaving 1,551 shares worth $7.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1324.

Essential Partners first reported a position in VNDA in Q2 2025 and has held it in 6 quarters since. The position peaked at $24.6K in Q4 2025. 9 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

Essential Partners held 1,551 shares of Vanda Pharmaceuticals worth $7.62K as of Q3 2026.
Essential Partners sold 1,258 Vanda Pharmaceuticals shares in Q3 2026, an estimated $6.76K.
Vanda Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1324 holding.
Essential Partners first reported a position in Vanda Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Vanda Pharmaceuticals position peaked at $24.6K in Q4 2025.
9 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.